Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jstrokecerebrovasdis.2021.105817 http://scihub22266oqcxt.onion/10.1016/j.jstrokecerebrovasdis.2021.105817 33933349!8041145!33933349     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33933349&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Stroke+Cerebrovasc+Dis 2021 ; 30 (7): 105817 Nephropedia Template TP {{tp|p=33933349|t=2021. Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19 |pdf=|usr=}}{{33933349}} gab.com Text Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19 JO: J Stroke Cerebrovasc Dis http://www.kidney.de/pget.php?&tw=1&pmid=33933349 #FOAvip Hypercoagulability and virally-mediated vascular inflammation have become well-recognized features of the SARS-CoV-2 virus infection, COVID-19. Of growing concern is the apparent ineffectiveness of therapeutic anticoagulation in preventing thromboembolic events among some at-risk patient subtypes with COVID-19. We present a 43-year-old female with a history of seropositive-antiphospholipid syndrome and systemic lupus erythematosus who developed an acute ischemic stroke in the setting of mild COVID-19 infection despite adherence to chronic systemic anticoagulation. The clinical significance of SARS-CoV-2-mediated endothelial cell dysfunction and its potential to cause macrovascular events in spite of full anticoagulation warrants further investigation and likely represents another disease-defining pathology of COVID-19. Twit Text FOAVip Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19 ????J Stroke Cerebrovasc Dis http://www.kidney.de/pget.php?&tw=1&pmid=33933349 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33933349 #FOAvip English Wikipedia <ref>{{Cite pmid|33933349}}</ref> Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19 #MMPMID33933349 Kincaid KJ; Simpkins AN J Stroke Cerebrovasc Dis 2021[Jul]; 30 (7): 105817 PMID33933349show ga Hypercoagulability and virally-mediated vascular inflammation have become well-recognized features of the SARS-CoV-2 virus infection, COVID-19. Of growing concern is the apparent ineffectiveness of therapeutic anticoagulation in preventing thromboembolic events among some at-risk patient subtypes with COVID-19. We present a 43-year-old female with a history of seropositive-antiphospholipid syndrome and systemic lupus erythematosus who developed an acute ischemic stroke in the setting of mild COVID-19 infection despite adherence to chronic systemic anticoagulation. The clinical significance of SARS-CoV-2-mediated endothelial cell dysfunction and its potential to cause macrovascular events in spite of full anticoagulation warrants further investigation and likely represents another disease-defining pathology of COVID-19. |Adult[MESH] |Anticoagulants/*therapeutic use[MESH] |Antiphospholipid Syndrome/blood/complications/diagnosis/*drug therapy[MESH] |Biomarkers/blood[MESH] |COVID-19/*complications/diagnosis[MESH] |Female[MESH] |Humans[MESH] |Ischemic Stroke/diagnostic imaging/*etiology/prevention & control[MESH] |Lupus Coagulation Inhibitor/*blood[MESH] |Risk Factors[MESH]Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Assoc(epmc).pdf DeepDyve Pubget Overpricing